Abstract:B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies. B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related death in young people and commonly has poor outcomes in adults. Dysregulation of cytokine signaling frequently occur in high-risk ALL and correlates with poor prognosis. Molecular insight into activation of oncogenic cytokine signaling comes from the recent discovery of loss-of-function mutations in the adaptor protein LNK (or SH2B3) and constitutive active JAK2 mutations in Ph-like pediatric B-ALL, the subtype that lacks Philadelphia (Ph) chromosome translocation, yet displays a similar activated kinase signature to Ph+ ALL. While clearly established at the genetic level, mechanisms by which LNK mutation impacts ALL initiation or progression have not been established. Here we show that LNK synergizes with TP53 in suppressing B-ALL development in mice. Lnk-/-Tp53-/- B-ALLs are highly aggressive with 100% penetrance. More importantly, Lnk-/-Tp53-/- B blasts specifically exhibit gene signatures of human Ph-like ALL. Mechanistically, we demonstrate that B progenitors from preleukemic Lnk-/-Tp53-/- mice are hypersensitive to IL-7 and display marked self-renewal ability in vitro and in vivo. Using a novel phosphoflow strategy that enables interrogation of early transformative signaling events in B progenitors at different stages, we find that Lnk deficiency confers a heightened sensitivity to IL-7 in activating pStat5 in pro B progenitors. Furthermore, Lnk-/-Tp53-/- B blasts show constitutive activation of pAkt and pS6, but still depend on IL-7 for activation of Stat5. Moreover, Lnk-/-Tp53-/- B blasts are less sensitive to JAK inhibitors than normal B progenitors, consistent with the inability of JAK inhibition to eradicate B-ALL in humans. High-risk B-ALLs that show genetic mutations in cytokine dependent pathways and elevated cytokine signaling have poor survival rates. Our research focuses on a novel B-ALL mouse model to decipher mechanisms underlying high-risk ALL, and will enhance our understanding of this incurable disease and provide novel insights into therapeutic strategies.

PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression

PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

PHF6 loss reduces leukemia stem cell activity in an acute myeloid leukemia mouse model

Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia

PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia

JAK Mutations in High-Risk Childhood Acute Lymphoblastic Leukemia.

PHF6 Mutation is Associated with Poor Outcome in Acute Myeloid Leukaemia.

Mutations that collaborate with IL-7Ra signaling pathways to drive ALL

Non-coding Germline GATA3 Variants Alter Chromatin Topology and Contribute to Pathogenesis of Acute Lymphoblastic Leukemia

Leukemia-mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness

A novel tumor suppressor sh2b3 in acute lymphoblastic leukemia

The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.

Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting

Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia

Combined heterozygosity of FLT3 ITD, TET2, and DNMT3A results in aggressive leukemia

PHF6 suppresses self-renewal of leukemic stem cells in AML

Notch1 Mutations In T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance And Implication In Multifactorial Leukemogenesis

Nutlin-3 Plus Tanshinone IIA Exhibits Synergetic Anti-Leukemia Effect with Imatinib by Reactivating P53 and Inhibiting the AKT/mTOR Pathway in Ph+ ALL

An Integrated Classification of Tumor Suppressor IKZF1 Inactivation and Oncogenic Activation in Philadelphia Chromosome‐like Acute Lymphoblastic Leukemia

EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism